Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
LogicBio Therapeutics, Inc. LOGC
$2.07
На 18:01, 12 мая 2023
+69.08%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
3.40
-
week52low
0.26
-
Revenue
5410000
-
P/E TTM
-2
-
Beta
4.61791700
-
EPS
-1.11600000
-
Last Dividend
0.00000000
-
Next Earnings Date
14 ноя 2022 г. в 05:00
Описание компании
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 22 авг 2022 г. |
| Chardan Capital | Buy | Buy | 17 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 10 мая 2022 г. |
| William Blair | Market Perform | Outperform | 03 февр 2022 г. |
| Chardan Capital | Hold | Hold | 02 февр 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kay Mark A | D | 0 | 12500 | 16 ноя 2022 г. |
| Kay Mark A | D | 0 | 12500 | 16 ноя 2022 г. |
| Nacht Mariana | D | 0 | 100000 | 16 ноя 2022 г. |
| Enyedy Mark J | D | 0 | 12500 | 16 ноя 2022 г. |
| Enyedy Mark J | D | 0 | 12500 | 16 ноя 2022 г. |
| Chereau Frederic | D | 0 | 328000 | 16 ноя 2022 г. |
| Chereau Frederic | D | 0 | 328000 | 16 ноя 2022 г. |
| WYZGA MICHAEL S | D | 0 | 12500 | 16 ноя 2022 г. |
| WYZGA MICHAEL S | D | 0 | 12500 | 16 ноя 2022 г. |
| Goater Jeff | D | 0 | 12500 | 16 ноя 2022 г. |
Новостная лента
Why Is LogicBio (LOGC) Stock Up 600% Today?
InvestorPlace
03 окт 2022 г. в 10:33
Source: Roland Magnusson / Shutterstock.com LogicBio (NASDAQ: LOGC ) stock is seeing massive gains on Monday following news that AstraZeneca (NASDAQ: AZN ) subsidiary Alexion is acquiring the clinical-stage genetic medicine company. The deal has Alexion agreeing to a cash tender offer for all outstanding shares of LOGC stock.
Why AstraZeneca (AZN) Is Buying LogicBio Therapeutics (LOGC) In About A $68 Million Deal
Pulse2
03 окт 2022 г. в 09:27
LogicBio Therapeutics, Inc. (LOGC) announced it is being acquired in a deal valued at about $68 million. These are the details.
5 Big Winners as Dollar Strengthens on Fed Rate Hike
Zacks Investment Research
27 сент 2022 г. в 09:47
A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.
5 Winning Stocks Backed by the Overlooked Trick of Rising P/E
Zacks Investment Research
27 сент 2022 г. в 09:02
Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI).